P1604Prevalence of obstructive sleep apnea in patients with cardiac sarcoidosis and its influences to physical and mental health

Abstract

Background: Fatigue is a common symptom in sarcoidosis. Obstructive sleep apnea (OSA) is a treatable cause of fatigue and sleepiness. In cardiac sarcoidosis (CS), all patients are treated with corticosteroids that often results in significant weight gain and thus predispose to OSA. Purpose(s): To determine the prevalence of OSA in CS and determine the effect of OSA on adverse cardiac events and the health-related quality of life (HRQOL). Method(s): Biopsy-verified CS patients were screened for OSA between February 2013 and December 2016 using polysomnography or home sleep testing devices Embletta or ApneaLink. Patients completed in January 2017 RAND-36 (general health-related quality of life questionnaire), FSS (Fatigue Severity Scale) and BDI (Beck Depression Inventory) questionnaires. Clinical data was retrieved from registry of myocardial inflammatory diseases. Result(s): This study included a total of 106 CS patients of which 74 (70%) were female and mean age was 53,9+/-10,7. Of 106 patients, OSA was diagnosed in 18 patients (17%) (prevalence in general population is 2-4%). No significant differences between groups (with or without OSA) in age, gender, depression or reduced LV dysfunction were found. Consistent with prior studies, BMI correlated with OSA (BMI with OSA 30,7 vs without OSA 26,7, p=0,001). All these patients were treated according to current guidelines. OSA did not result in higher rate of ventricular arrhythmias (VT/VF) (log-rank test p=0,522). Fatigue was significantly more common symptom in CS patients with treated OSA (FSS normal value